Calcium-sensing receptor activator cinacalcet for treatment of cyclic nucleotide-mediated secretory diarrheas

Transl Res. 2024 Jan:263:45-52. doi: 10.1016/j.trsl.2023.09.001. Epub 2023 Sep 9.

Abstract

Cyclic nucleotide elevation in intestinal epithelial cells is the key pathology causing intestinal fluid loss in secretory diarrheas such as cholera. Current secretory diarrhea treatment is primarily supportive, and oral rehydration solution is the mainstay of cholera treatment. There is an unmet need for safe, simple and effective diarrhea treatments. By promoting cAMP hydrolysis, extracellular calcium-sensing receptor (CaSR) is a regulator of intestinal fluid transport. We studied the antidiarrheal mechanisms of FDA-approved CaSR activator cinacalcet and tested its efficacy in clinically relevant human cell, mouse and intestinal organoid models of secretory diarrhea. By using selective inhibitors, we found that cAMP agonists-induced secretory short-circuit currents (Isc) in human intestinal T84 cells are mediated by collective actions of apical membrane cystic fibrosis transmembrane conductance regulator (CFTR) and Clc-2 Cl- channels, and basolateral membrane K+ channels. 30 μM cinacalcet pretreatment inhibited all 3 components of forskolin and cholera toxin-induced secretory Isc by ∼75%. In mouse jejunal mucosa, cinacalcet inhibited forskolin-induced secretory Isc by ∼60% in wild type mice, with no antisecretory effect in intestinal epithelia-specific Casr knockout mice (Casr-flox; Vil1-cre). In suckling mouse model of cholera induced by oral cholera toxin, single dose (30 mg/kg) oral cinacalcet treatment reduced intestinal fluid accumulation by ∼55% at 20 hours. Lastly, cinacalcet inhibited forskolin-induced secretory Isc by ∼75% in human colonic and ileal organoids. Our findings suggest that CaSR activator cinacalcet has antidiarrheal efficacy in distinct human cell, organoid and mouse models of secretory diarrhea. Considering its excellent clinical safety profile, cinacalcet can be repurposed as a treatment for cyclic nucleotide-mediated secretory diarrheas including cholera.

Keywords: CFTR; Cholera; Drug repurposing; Traveler's diarrhea; VIPoma.

MeSH terms

  • Animals
  • Antidiarrheals* / metabolism
  • Antidiarrheals* / pharmacology
  • Antidiarrheals* / therapeutic use
  • Cholera Toxin / metabolism
  • Cholera Toxin / pharmacology
  • Cholera Toxin / therapeutic use
  • Cholera* / drug therapy
  • Cholera* / metabolism
  • Cholera* / pathology
  • Cinacalcet / metabolism
  • Cinacalcet / pharmacology
  • Cinacalcet / therapeutic use
  • Colforsin / metabolism
  • Colforsin / pharmacology
  • Colforsin / therapeutic use
  • Cystic Fibrosis Transmembrane Conductance Regulator / metabolism
  • Cystic Fibrosis Transmembrane Conductance Regulator / therapeutic use
  • Diarrhea / drug therapy
  • Diarrhea / metabolism
  • Humans
  • Intestinal Mucosa / metabolism
  • Mice
  • Mice, Knockout
  • Nucleotides, Cyclic / metabolism
  • Nucleotides, Cyclic / pharmacology
  • Nucleotides, Cyclic / therapeutic use
  • Receptors, Calcium-Sensing / metabolism
  • Receptors, Calcium-Sensing / therapeutic use

Substances

  • Antidiarrheals
  • Cholera Toxin
  • Cinacalcet
  • Receptors, Calcium-Sensing
  • Nucleotides, Cyclic
  • Colforsin
  • Cystic Fibrosis Transmembrane Conductance Regulator